Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Substance-Related Disorders × Acceptance and Commitment Therapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7 Fatigue 6 Breast Neoplasms 4 Anxiety Disorders 3 Psychological Well-Being 2 Pain 2 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Esophageal Neoplasms 2 Depression 2 Caregiver Burden 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Substance-Related Disorders 1 Smoking Cessation 1 Sleep Wake Disorders 1 Sleep Initiation and Maintenance Disorders 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasm Regression, Spontaneous 1 Multiple Myeloma 1 Malignant Hepatobiliary Neoplasm 1 Lymphoma 1 Leukemia 1 Hematopoietic Cell Transplantation Recipient 1 Head and Neck Neoplasms 1 Glioblastoma 1

Interventions

Ultrasonic Waves 1 Tobacco Use Cessation Devices 1 Therapeutics 1 Surveys and Questionnaires 1 Patient Reported Outcome Measures 1 Nicotine Replacement Therapy 1 Nicotine Chewing Gum 1 Focus Groups 1 Ethanol 1 Educational Status 1 Dosage Forms 1 Cognitive Behavioral Therapy 1 Behavior Therapy 1 Acceptance and Commitment Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05643027 2025-12-05

ACTION

Dana-Farber Cancer Institute

Phase NA Recruiting

Neoplasms, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡